Cutting-Edge Drug Discovery1910 Genetics utilizes advanced AI models and laboratory automation to accelerate drug discovery for neurological, autoimmune diseases, and cancer, offering potential solutions to pharmaceutical partners seeking novel drug candidates.

Industry-Leading AI TechnologyWith the launch of innovative AI models such as CANDID-CNS and advanced blood-brain barrier drug permeability prediction tools, 1910 Genetics stands out in the biotechnology research field, presenting an opportunity for collaborations with companies looking to leverage cutting-edge technology.

Strong Investor BackingBacked by prominent investors including M12 - Microsoft's Venture Fund, Playground Global, and Y Combinator, 1910 Genetics has financial stability and strategic support, providing a potential partnership opportunity for businesses aligning with these investors.

Expert Leadership TeamWith a notable board of directors and key personnel appointments like Dr. Shaan C. Gandhi and Bridget Cole, 1910 Genetics showcases a strong leadership foundation, offering a potential collaboration avenue for companies looking to work with experienced industry professionals.

Government and Institutional SupportHaving received substantial funding from the National Institutes of Health, 1910 Genetics demonstrates credibility and validation from governmental institutions, potentially attracting partnerships with organizations seeking to align with well-supported and recognized entities in the biotechnology sector.